N/A N=9 Collaborating to Implement Cross-System Interventions in Child Welfare and Substance Use
Substance Use · Implementation · Child Maltreatment
Primary: Perceived Acceptability — 4.3 Scale points
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=88 Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
Yellow Fever Vaccination Reaction
Primary: Adverse Events — 26; 27; 28 Participants
N/A N=5 The Impact of Environmental Controls on Mental Health
Neurologic Disorders
Primary: Percentage of Participants Achieving MCID in PROMIS Global10 Score. — 5 Participants
Phase 2 N=21 Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
Urticaria
Primary: Effect of ARS-1 Versus Placebo Based on a Patient Reported Pruritus/Hive Score — 1.1; 0.8; 1.8; 0.4 UAS score 0 to 3
N/A N=274 Pre-arrival Instructions Effect on Bystander Cardiopulmonary Resuscitation (CPR).
Heart Arrest · Cardiac Arrest · Cardiopulmonary Arrest
Primary: Incidence of Bystander Cardiopulmonary Resuscitation (CPR) in Out of Hospital Cardiac Arrest (OHCA) — 11; 19; 42; 25 participants — p=0.41
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
Phase 4 N=96 Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy
Photorefractive Keratectomy · Corneal De-epithelialization
Primary: Changes in Corneal Re-epithelialization (Time) — 5.39; 5.34 days
Phase 4 N=3,729 OPV as Potential Protection Against COVID-19
Poliovirus Vaccine, Oral · COVID · Mortality
Primary: Mortality or Infectious Disease Causing Consultation or Admission (Composite Outcome) — 169; 239 Participants
Phase 2 N=42 Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
Acute Myeloid Leukemia
Primary: Duration of Remission Response to Azacitidine and Venetoclax Treatment + Maintenance Therapy — 12.9 months
N/A N=18 Enhancing Skeletal Adaptations to PTH and Exercise
Exercise · Bone Resorption · Bone Formation
Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL
N/A N=452 Study of Impact of Not Measuring Residual Gastric Volume on Nosocomial Pneumonia Rates
Ventilation-Associated Pneumonia
Primary: Compare Ventilator Associated Pneumonia Rates in Patients Receiving Early Enteral Feeding Without Residual Gastric Volume (RGV) Monitoring and in Patients With RGV…
N/A N=30 Effects of Electronic Cigarette Flavors on Abuse Liability in Smokers (P3-Taste)
Electronic Cigarette Use
Primary: Intensity of Drug Purchase Task (DPT) — 172.20; 89.90; 60.83; 94.50 number of puffs
Phase 3 N=367 Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 100; 167; 31; 298 Participants
Phase 2 N=229 An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Advanced Cancer
Primary: Number of Participants With Grade 3/Grade 4 Laboratory Test Results — 0; 0; 0; 0 Participants
Phase 3 N=1,990 Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
Papillomavirus Infections
Primary: Stage I: Competitive Luminex Immunoassay (cLIA) Geometric Mean Titers (GMTs) for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age and…